| January 2018 | The multinational consortium MCDS-therapy has been granted 5.7 Million Euro by the European Commission for the development of novel therapeutic approaches in rare skeletal disorders. Sciomics' expertise with the antibody microarray technology herein serves as a valuable tool for biomarker identification and personalized treatment monitoring. > Press release
| March 2021 | Scientists at Heidelberg University Hospital characterized the protein profile response of an endometrial cell line to Metformin treatment and hyperinsulinemia with our scioDiscover platform:
"The presented data helps identify potential targets affected by metformin treatment in EC and allows for a better understanding of the mechanism of action of the biguanide drug’s anti-cancer activity.
With the presented data, we contribute to a better understanding of the anti-cancer activity of metformin as well as its underlying mechanism of action in EC cells."
Lange, C. et al. (2021) ‘Changes in protein expression due to metformin treatment and hyperinsulinemia in a human endometrial cancer cell line’, PLoS ONE 16(3):e0248103. https://doi.org/10.1371/journal.pone.0248103
| Feb 2021 | Scientists at Heidelberg University Hospital used our scioCD platform to profile CD8+SLAMF7+ cell cultures:
"High throughput screening of 351 different cytokines and immune proteins in the supernatants of the T cells cultures revealed strong upregulation of IL-6, IL-8, both vital survival factors for myeloma cells, and CXCL5, a chemokine that could enhance the frequency of CD4 Treg, in the cultures containing CD8+SLAMF7+ cells. IL-2 and IL-5 were upregulated in the control cultures without CD8+SLAMF7+ T cells, highlighting a more activated state in the control group and suggestion IL-6 and IL-8 as potential effector cytokines for the suppressive CD8+SLAMF7+ T cells."
Awwad, M. H. S. et al. (2021) ‘Selective elimination of immunosuppressive T cells in patients with multiple myeloma’, Leukemia, pp. 1–14. doi: 10.1038/s41375-021-01172-x.
| Feb 2021 | Scientists at Rostock University Medical Center used our scioCD platform to Corneal Epithelial Cells stimulated with Alternating Current Electric Fields:
"Analysis of the protein array data revealed that the treatment of cells with AC EFs altered the expression of various protein products ... revealed activation of various diverse cellular signaling pathways in which TNF, MAPK, IL17, and PI3K-Akt signaling pathways were significantly impacted ..."
B. S. Kowtharapu et. al., „Analysis of the Differential Gene and Protein Expression Profiles of Corneal Epithelial Cells Stimulated with Alternating Current Electric Fields“, Genes, Bd. 12, Nr. 2, Art. Nr. 2, Feb. 2021, doi: 10.3390/genes12020299.
| Dec 2020 | Scientists at University of Sassari used our scioPhospho platform to to analyse the synergy of BET and PARP inhibition in Small Cell Lung Cancer Cells:
"Among the I-BET762-associated and combination-associated differentially expressed proteins, 150 were common to both treatment conditions. ... Ranking I-BET762-associated and combination-associated DEPs by their differential expression revealed CHEK2 and PTEN to be among the top-downregulated proteins, whose deficiencies have been associated with HR defects and increased PARPi sensitivity. "
Fiorentino, F. P. et al. (2020) ‘BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells’, International Journal of Molecular Sciences, 21(24). doi: 10.3390/ijms21249595.
| Jan 2019 | In the article, scientists at Tel Aviv University used our scioDiscover platform to analyse tumor-associated eosinophils in colorectal cancer. The full article is published in Cancer Immunology Research.
Prof. Dr. Andreas Weigert
Goethe-University Frankfurt, Faculty of Medicine, Institute of Biochemistry I, Frankfurt, Germany
"We were under considerable time pressure to gain comprehensive information about cytokine/chemokine levels in a mouse model of self-resolving inflammation. To add to our misery, we had only a small number of biological replicates to run the analyses. Thankfully, the team at Sciomics were able to come to our rescue by providing a very prompt analysis, without neglecting to properly communicate the procedure, potential caveats and other details. The whole process was a very satisfying experience, rather like working with committed colleagues than with a company, and we got great data out of the project. I do happily recommend working with Sciomics for targeted proteomics analyses."
Product: scioCD
Tune into our CEO Dr. Christoph Schröder’s @ChristophSch78 exciting talk: “Prediction of severe COVID-19 disease –… https://t.co/FrAB76Rij7
Join us at this year's BIO Digital virtual conference and learn how we can push your research forward with our prot… https://t.co/8eKhFB8Hmm
RT @MCDS_Therapy: #DidYouKnow That 25 years have passed and there is STILL no #Treatment for #MCDS? We're working to change that💪 View th…
Sciomics is celebrating its 8th birthday this month, so we decided to add another array to our repertoire: scioCake… https://t.co/OYdtwl872y
Join us at Nordic Life Science Days virtual partnering conference @NLSDays and learn how we can advance your resear… https://t.co/u3eKUmn7G4